BeiGene Announces approval for its three oncology products in China

Date: 2020-12-29   Author: Saipriya Iyer  Category: #news

BeiGene Announces approval for its three oncology products in China

BeiGene Ltd., one of the leading Chinese commercial-stage biotechnology firms focused on commercializing and developing innovative medicines, has reportedly announced that it has received approval from the NHSA (China National Healthcare Security Administration) for three of its oncology medicines.

Sources cite that the NHSA has included anti-PD-1 antibody tislelizumab, XGEVA® (120-mg denosumab), and BTK inhibitor BRUKINSA® (zanubrutinib) to its updated NRDL (National Reimbursement Drug List).

Speaking on which, Xiaobin Wu, Ph.D., President of BeiGene said that the NRDL’s addition of tislelizumab, BRUKINSA, and XGEVA would help expand access to these top-quality oncology treatments in the nation and ease the financial burden for patients suffering from cancer and their families. The company believes that the approval could have a profound impact on patients in the nation that is accountable for one-fourth of the world’s cancer patients each year.

He added that the company is appreciative of its team’s efforts and its partnership in developing and commercializing these medicines, and understands that this accomplishment wouldn’t have been possible without the nation’s commitment to high-quality treatments and innovation through ongoing drug reform and the Healthy China initiative.

With these NRDL inclusions, the company is making substantial strides towards the  its mission, which at its core is to strengthen access to and enhance impactful innovative medicines’ affordability for patients worldwide, Dr. Wu said, while adding that the company is looking forward to more exciting progress on this endeavor.

XGEVA® from BeiGene’s partnership with Amgen is included in one approved indication. It has received conditional approval in the nation as a treatment for SREs (Skeletal-related events) in patients with bone metastases from solid tumors and in patients with MM (Multiple Myelona), which wasn’t eligible for 2020 NRDL considerations as it was authorized after the cut-off date.

For the record, BeiGene is a biopharmaceutical firm focused on introducing molecularly targeted and immuno-oncology drug candidates for treating cancer.

Source credit - https://www.businesswire.com/news/home/20201227005018/en/BeiGene-Announces-Inclusion-of-Three-Innovative-Oncology-Products-in-China-National-Reimbursement-Drug-List-NRDL



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

63 moons to offer next-gen tech to Spuma SRL in pan-European market expansion

Author: Saipriya Iyer

63 moons technologies, a world leader in providing next-generation technology platforms, has recently announced its plans to boost and back Italy-located Spuma SRL, with its next-generation technological abilities and ...


Global Joint Reconstruction Devices Market to Observe Strong Development during the Forecast Period 2021 to 2027

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Joint Reconstruction Devices market’. This report sheds light on the analysis of the industry chall...


Surgical Robots Market is poised to grow at a Healthy CAGR between 2022 to 2030

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Surgical Robots market’. This report sheds light on the analysis of the industry challenges, growth opportunities, industry threats, ...